-
Lonza Publishes Restated Financials for 2020
Lonza reports restated 2020 financials for sales, EBIT, EBITDA and CORE EBITDA Lonza now provides 2020 financials in the redesigned business structure to reflect divisional performance Prior to the reporting of the Half-Year Results 2021 on 23 July 2021, Lonza today is providing restated financials to reflect: The classification of Lonza’s Specialty Ingredients (LSI) business as discontinued operations for Half-Year Result 2020 (consistent with Full-Year 2020 Reporting) Lonza’s redesigned business structure The revised Alternative Performance Measure (APM) policy In July 2020, Lonza announced the decision to divest the Specialty Ingredients business via a sale process. Consequently, the LSI operations results were reported as discontinued operations for the Full-Year 2020. The…
-
Lonza Announces Results of the 2021 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
47,080,080 shareholders delegated their votes to the independent proxy, representing 63.22% of the share capital Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors for another year A dividend of CHF 3.00 per share will be paid out starting from 12 May 2021 Today, Lonza Group Ltd hosted its Annual General Meeting, led by the Chairman of the Board of Directors, Albert M. Baehny. Due to the ongoing COVID-19 pandemic, no shareholders were admitted to attend the Annual General Meeting in person. Lonza had previously recommended that shareholders delegate their votes to the independent proxy on 25 March…
-
Lonza Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities in Visp (CH) and Portsmouth (US)
. Lonza will invest approximately CHF 850 million to build two new state-of-the-art mammalian facilities and respond to customer demand regarding capacity, life cycle management and speed to market A new large-scale facility with the latest manufacturing technology in Visp (CH), will expand capacity by six 20,000L bioreactors to meet increasing market demand for biologics Small-scale, single-use technology facility planned for Portsmouth (US) to support customers scaling clinical to commercial manufacturing with capacity for up to eight 2,000L bioreactors The investment is supported by a strong pipeline and underlines Lonza’s continuing commitment to serving customers across modalities and scales Quote from Pierre-Alain Ruffieux, CEO, Lonza: “As we look at the…
-
Lonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp
Lonza will invest CHF 200 million to construct a new manufacturing complex The 2000 m2 complex will include a customer dedicated manufacturing line for antibody-drug conjugate payload molecules The investment is supported by a long-term collaboration and capital contribution with a major biopharmaceutical partner The new manufacturing complex is designed to accommodate future small molecule expansions Quote from Maurits Janssen, Strategic Business Development Small Molecules, Lonza: “Supply is critical for our global partner in the oncology field. With this investment, we are enabling the treatment of many cancer patients. Oncology continues to be the leading indication in biopharma and a key driver for highly potent ingredients such as antibody-drug…
-
Lonza finalise la cession de deux sites à NextPharma
Finalisation de la vente des sites Lonza de Ploermel (FR) et d’Edimbourg (UK) Un processus de transfert de propriété sans heurts reste une priorité Citation de Gordon Bates, président et responsable de la division Small Molecules, Lonza : "La cession stratégique de nos sites de Ploermel et d’Édimbourg permettra à NextPharma de bénéficier de synergies opérationnelles et d’optimiser l’expertise et les technologies existantes. Dans ce contexte, alors que nous clôturons le processus de cession, nous sommes convaincus que NextPharma est bien placée pour développer et faire croître les deux sites à leur plein potentiel. Nous souhaitons remercier les équipes de direction et les employés des sites de Ploermel et d’Édimbourg…
-
Lonza Completes Divestment of Two Sites to NextPharma
Completion of sale of Lonza sites in Ploermel (FR) and Edinburgh (UK) A seamless ownership transfer process remains a priority Quote from Gordon Bates, President and Head of Small Molecules, Lonza: “The strategic divestment of our Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies. In this context, as we close the divestment process, we are confident that NextPharma is well placed to develop and grow both sites to their full potential. We wish to thank the leadership teams and employees at the Ploermel and Edinburgh sites for their continuing dedication and professionalism during the transition period.” Quote from Peter Burema,…
-
Lonza Signs Agreement to Divest Specialty Ingredients Business to Bain Capital and Cinven
Lonza Specialty Ingredients to be sold to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion Divestment will allow Lonza to refocus its business as a pure-play partner to the healthcare industry Successful track record of investment in industrials sector and portfolio companies confirms that Bain Capital and Cinven are the right home for the business Smooth transition for employees and customers is a priority for both seller and buyers. The transaction is anticipated to close in H2 2021 Quote from Albert M. Baehny, Chairman, Lonza: “Today’s announcement is the result of a comprehensive and robust selection process. Bain Capital and Cinven have shown they…
-
Lonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business
Lonza delivers on guidance1 with CHF 4.5 billion sales, 12.0%2 sales growth, and CHF 1.4 billion CORE EBITDA, resulting in a 31.2% margin Lonza results mainly reflect Pharma Biotech & Nutrition (LPBN) performance, as Specialty Ingredients (LSI) is reported as a discontinued operation Strong LPBN performance: 12.2%2 sales growth and 32.1% CORE EBITDA margin Production of the drug substance for Moderna COVID-19 Vaccine has commenced at Portsmouth (USA) and Visp (CH) sites Executive Committee expanded to ensure divisional representation, effective as of 1 April 2021 2021 Outlook: low double-digit CER sales growth, with a CORE EBITDA margin improvement aligned with the recently announced Mid-Term 2023 Guidance LSI3 delivered 3.4%2 sales growth and 20.3%4 CORE…
-
NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms
. Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology offering into lipid finished dosage forms Centers of excellence employing a total of 390 staff offer expertise in Lipid Oral Dosage Forms including softgels and liquid-filled hard capsules for the pharma and nutrition markets Sustainable growth and people development a priority for both companies Quote from Gordon Bates, President and Head of Small Molecules, Lonza: “NextPharma is an established and well-respected company, with extensive experience in oral and topical finished dosage forms. As such, it is the ideal buyer given the technologies available at the Ploermel and Edinburgh sites.…
-
Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates
Two new bioconjugation suites to provide high throughput conjugation for the commercialization of antibody-drug conjugates (ADCs) in Lonza’s Ibex®Dedicate 1500m2 of active manufacturing space in addition to established quality control (QC) labs, logistics and other central services Long-term collaboration with a global biopharma company will generate around 200 new jobs in Visp (CH) biopark, with operations expected to start from end 2022 Quote from Pierre-Alain Ruffieux, CEO, Lonza: "Bioconjugates represent an exciting class of molecules that are proving their worth and making a real difference to patients suffering from diseases such as cancer. From a manufacturing point of view, antibody-drug conjugates are challenging to produce, and we will be ensuring…
